Wuhan Keqian BiologyLtd Future Growth
Future criteria checks 5/6
Wuhan Keqian BiologyLtd is forecast to grow earnings and revenue by 25% and 20% per annum respectively. EPS is expected to grow by 24.7% per annum. Return on equity is forecast to be 12.3% in 3 years.
Key information
25.0%
Earnings growth rate
24.7%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 20.0% |
| Future return on equity | 12.3% |
| Analyst coverage | Good |
| Last updated | 10 Sep 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Wuhan Keqian BiologyLtd (SHSE:688526) Is Using Debt Reasonably Well
Sep 26
Investors Continue Waiting On Sidelines For Wuhan Keqian Biology Co.,Ltd (SHSE:688526)
Aug 20We Think Wuhan Keqian BiologyLtd (SHSE:688526) Can Stay On Top Of Its Debt
Jun 26Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Stock Rockets 25% But Many Are Still Ignoring The Company
Apr 08Analysts Are More Bearish On Wuhan Keqian Biology Co.,Ltd (SHSE:688526) Than They Used To Be
Apr 05Earnings Miss: Wuhan Keqian Biology Co.,Ltd Missed EPS By 25% And Analysts Are Revising Their Forecasts
Apr 03Wuhan Keqian BiologyLtd (SHSE:688526) Has A Rock Solid Balance Sheet
Mar 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,605 | 638 | 460 | 658 | 6 |
| 12/31/2025 | 1,377 | 553 | 399 | 604 | 7 |
| 12/31/2024 | 1,180 | 463 | 457 | 491 | 7 |
| 6/30/2024 | 933 | 309 | 385 | 478 | N/A |
| 3/31/2024 | 989 | 348 | 398 | 493 | N/A |
| 12/31/2023 | 1,064 | 396 | 434 | 538 | N/A |
| 9/30/2023 | 1,142 | 484 | 447 | 538 | N/A |
| 6/30/2023 | 1,139 | 490 | 374 | 460 | N/A |
| 3/31/2023 | 1,078 | 454 | 394 | 495 | N/A |
| 12/31/2022 | 1,001 | 410 | 321 | 424 | N/A |
| 9/30/2022 | 1,014 | 468 | 240 | 389 | N/A |
| 6/30/2022 | 952 | 444 | 238 | 438 | N/A |
| 3/31/2022 | 987 | 493 | 109 | 389 | N/A |
| 12/31/2021 | 1,103 | 571 | 157 | 531 | N/A |
| 9/30/2021 | 1,015 | 514 | 185 | 515 | N/A |
| 6/30/2021 | 1,033 | 551 | 261 | 562 | N/A |
| 3/31/2021 | 987 | 524 | 336 | 546 | N/A |
| 12/31/2020 | 843 | 448 | 289 | 400 | N/A |
| 9/30/2020 | 723 | 371 | 260 | 387 | N/A |
| 6/30/2020 | 576 | 271 | 80 | 194 | N/A |
| 3/31/2020 | 539 | 258 | 91 | 220 | N/A |
| 12/31/2019 | 508 | 243 | 17 | 155 | N/A |
| 12/31/2018 | 735 | 389 | 320 | 352 | N/A |
| 12/31/2017 | 633 | 320 | N/A | 338 | N/A |
| 12/31/2016 | 390 | 186 | N/A | 221 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688526's forecast earnings growth (25% per year) is above the savings rate (2.9%).
Earnings vs Market: 688526's earnings (25% per year) are forecast to grow faster than the CN market (22.9% per year).
High Growth Earnings: 688526's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688526's revenue (20% per year) is forecast to grow faster than the CN market (13.1% per year).
High Growth Revenue: 688526's revenue (20% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688526's Return on Equity is forecast to be low in 3 years time (12.3%).